Is Thymosin Alpha-1 Legal in South Carolina?
HealthRX.com
No federal approval for thymosin alpha-1, and SC rules are unclear
At a glance
- FDA approval / None in the US; orphan designations are not approvals [1]
- Pharmacy compounding list / Not in any of the three categories for state-licensed pharmacies and physicians [2]
- Outsourcing facilities / Category 3, 'nominated without adequate support' [3]
- FDA advisory vote / 4 yes, 17 no on adding it to the pharmacy bulks list [4]
- HHS peptide draft / Not among the six peptides in the October 2026 draft policy [5]
- Other countries / Approved in Italy, India and Hong Kong [1]
What is the federal legal position?
Thymosin alpha-1, also called thymalfasin, has no FDA-approved application [1]. FDA's December 2024 review notes four US orphan drug designations, but orphan designation is a separate process from approval and is not an approval [1]. Zadaxin is the brand of the finished injection sold outside the US and is not interchangeable with bulk thymosin alpha-1 powder [1].
FDA's list for state-licensed pharmacies and physicians does not include thymosin alpha-1 in any of its three categories [2]. On FDA's list for outsourcing facilities, it is in category 3, 'nominated without adequate support' [3]. FDA's category 1 policy, which generally says the agency will not act against compounders if conditions are met, does not apply to it [2][3].
In December 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and acetate forms. Members who voted no cited no compelling evidence of clinical effectiveness and safety [4]. FDA had proposed that thymosin alpha-1 not be added to the pharmacy bulks list [4].
Does FDA still list safety concerns?
Yes. FDA's page on bulk substances that may raise significant safety risks lists thymosin alpha-1 in the 'nominated but withdrawn' table. It had been in category 2, and it came off because the nominators withdrew. FDA's stated concerns remain: significant risk for immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information that FDA called inadequate to understand the extent of any safety issues [6].
Thymosin alpha-1 is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5].
Is it approved outside the US?
Yes. FDA's December 2024 review lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; and Hong Kong [1]. Those approvals are not US approvals [1].
What about South Carolina?
The federal picture is the same in South Carolina as elsewhere: thymosin alpha-1 is not FDA-approved [1], it is not listed for state-licensed pharmacy compounding [2], and it is in category 3 for outsourcing facilities [3]. FDA's information does not say whether South Carolina has a separate statute, Board of Pharmacy rule or Board of Medical Examiners guidance that names thymosin alpha-1.
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Questions worth asking
Frequently asked questions
What is the federal status of thymosin alpha-1?
Did FDA's advisory committee support compounding thymosin alpha-1?
Does FDA still list safety concerns for thymosin alpha-1?
Is thymosin alpha-1 approved in other countries?
Is thymosin alpha-1 in the HHS peptide policy?
Is thymosin alpha-1 on the WADA Prohibited List?
References
Show all 7 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency. 2026 Prohibited List